A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2024-06, Vol.109 (6), p.1994
Hauptverfasser:	Nakamura, Ryotaro, La Rosa, Corinna, Yang, Dongyun, Hill, Joshua A, Rashidi, Armin, Choe, Hannah, Zhou, Qiao, Lingaraju, Chetan Raj, Kaltcheva, Teodora, Longmate, Jeffrey, Drake, Jennifer, Slape, Cynthia, Duarte, Lupe, Al Malki, Monzr M, Pullarkat, Vinod A, Aribi, Ahmed, Devine, Steven, Verneris, Michael R, Miller, Jeffrey S, Forman, Stephen J, Aldoss, Ibrahim, Diamond, Don J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Cytomegalovirus - immunology Cytomegalovirus Infections - etiology Cytomegalovirus Infections - immunology Cytomegalovirus Infections - prevention & control Cytomegalovirus Vaccines - immunology Female Hematopoietic Stem Cell Transplantation - adverse effects Humans Male Middle Aged Transplantation, Homologous Virus Activation - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!